GH
Therapeutic Areas
TechImmune Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Long COVID Immunotherapy | Treatment of Long COVID / Post-Acute Sequelae of SARS-CoV-2 (PASC) | Pre-clinical |
| Acute COVID-19 Antiviral Therapy | Treatment of acute COVID-19, prevention of Long COVID | Pre-clinical |
Leadership Team at TechImmune
JF
James F. Young, PhD
Executive Chairman
JU
Jeffrey Ulmer, PhD
Chief Executive Officer and Board Member
LB
Lbachir BenMohamed, PhD
Vice President and Board Member
DG
Dan Gil, PhD
Chief Operating Officer and Board Member
CD
Chris Dedic
Chief Financial Officer